The blood level of the glial fibrillary acidic protein (GFAP) cellular component increases when astrocytes are damaged or activated. Elevated levels of GFAP in the blood can indicate both the current and future progression of multiple sclerosis.
A new blood test can detect the GFAP protein at elevated levels in blood samples up to ten years before symptoms of Alzheimer's disease are first noticeable in those with an inherited form of the neurodegenerative disorder.
The levels of two protein biomarkers, GFAP and UCH-L1 found in blood samples taken 24 hours after a traumatic brain injury can help to predict which patients will die and which will obtain a severe disability.
Higher levels of the GFAP protein in the blood could be used to diagnose Alzheimer's disease decades before symptoms appear.
Some coronavirus patients exhibit clinical and neurochemical signs of brain injury associated with the viral infection. COVID-19 patients who required ventilation had increased plasma NfL levels. The higher NfL concentration levels were linked to the severity of infection.
Methylation sites have been identified in multiple genes implicated in daytime sleepiness.
A new study find the deletion of a specific gene associated with schizophrenia leads to abnormal differentiation of neurons in the brain.
Researchers use a simple blood test to detect evidence of concussion in patients up to 7 days after injury has occurred.
Researchers discover some people with major depressive disorder are lacking astrocytes in some hippocampal areas.
Math models usually applied to physics studies are proving useful in studying the spatial distribution of astocytes in the brain, and are helping to develop new strategies for tackling Alzheimer's disease.
A blood test is able to detect concussions with 94 percent accuracy, a new study reports.
A new study reports networks of astrocytes are altered in areas of the brain associated with mood regulation in some people who committed suicide as a result of depression.
